Jan. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B ...
Hosted on MSN14d
Denali's ALS Study Fails to Meet Primary and Secondary EndpointsDNL343 is a novel small molecule ALS therapeutic candidate that targets eIF2B, a central regulator of the integrated stress response. Shares of DNLI have lost 6.5% in the past six months compared ...
DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the HEALEY trial.
Denali has two wholly-owned, late-stage development programs, DNL310 for Hunter syndrome and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). DNL310 or tividenofusp alfa is an ...
today announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B agonist DNL343 in the treatment of amyotrophic lateral sclerosis (ALS).
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback